UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 105

Sortiert nach

5-Year Outcomes with Cobimetinib plus Vemurafenib in BRAF V600 Mutation–Positive Advanced Melanoma: Extended Follow-up of the coBRIM Study

Clinical cancer research, 2021-10, Vol.27 (19), p.5225-5235

2021

Volltextzugriff (PDF)

5-Year Outcomes with Cobimetinib plus Vemurafenib in BRAFV600 Mutation-Positive Advanced Melanoma: Extended Follow-up of the coBRIM Study

Clinical cancer research, 2021-10, Vol.27 (19), p.5225-5235

2021

Volltextzugriff (PDF)

Abstract 4239: Ectopic expression of EWS-FLI1 in human neural crest stem cells induces polycomb genes and maintenance of stemness

Cancer research (Chicago, Ill.), 2010-04, Vol.70 (8_Supplement), p.4239-4239

2010

Volltextzugriff (PDF)

Abstract 5169: The polycomb group protein BMI-1 cooperates with Yes-Associated Protein, YAP, to suppress cell contact inhibition in Ewing sarcoma cells

Cancer research (Chicago, Ill.), 2010-04, Vol.70 (8_Supplement), p.5169-5169

2010

Volltextzugriff (PDF)

Abstract LB-233: Modeling Ewing sarcoma initiation in human neural crest stem cells

Cancer research (Chicago, Ill.), 2011-04, Vol.71 (8_Supplement), p.LB-233-LB-233

2011

Volltextzugriff (PDF)

Abstract LB-A09: EED targeted PROTACs degrade EED, EZH2, and SUZ12 in the PRC2 complex

Molecular cancer therapeutics, 2019-12, Vol.18 (12_Supplement), p.LB-A09-LB-A09

2019

Volltextzugriff (PDF)

Abstract PR03: Prmt1 and Prmt1-dependent translation initiation are critical vulnerabilities of osteosarcoma

Cancer research (Chicago, Ill.), 2016-03, Vol.76 (5_Supplement), p.PR03-PR03

2016

Volltextzugriff (PDF)

Abstract SY15-01: Modeling the initiation of Ewing sarcoma in human neural crest stem cells

Cancer research (Chicago, Ill.), 2011-04, Vol.71 (8_Supplement), p.SY15-01-SY15-01

2011

Volltextzugriff (PDF)

Acceptability and appropriateness of a novel parent-staff co-leadership model for childhood obesity prevention in Head Start: a qualitative interview study

BMC public health, 2021-01, Vol.21 (1), p.201-201, Article 201

2021

Volltextzugriff (PDF)

Adverse event (AE) incidence rates with cobimetinib (C) plus vemurafenib (V) treatment: Extended follow-up (f/u) of the phase III coBRIM study

Journal of clinical oncology, 2016-05, Vol.34 (15_suppl), p.9533-9533

2016

Volltextzugriff (PDF)

Amination-mediated nano eye-drops with enhanced corneal permeability and effective burst release for acute glaucoma treatment

Chemical engineering journal (Lausanne, Switzerland : 1996), 2023-01, Vol.451, p.138620, Article 138620

2023

Volltextzugriff (PDF)

Application of ion chromatography to the semiconductor industry: I. Measurement of acidic airborne contaminants in cleanrooms

Journal of Chromatography A, 1998-04, Vol.804 (1), p.273-278

1998

Volltextzugriff (PDF)

The association of BMI and outcomes in metastatic melanoma: A retrospective, multicohort analysis of patients treated with targeted therapy, immunotherapy, or chemotherapy

The lancet oncology, 2018-02, Vol.19 (3), p.310-322

2018

Volltextzugriff (PDF)

Association of Participation in the Oncology Care Model With Medicare Payments, Utilization, Care Delivery, and Quality Outcomes

JAMA : the journal of the American Medical Association, 2021-11, Vol.326 (18), p.1829

2021

Volltextzugriff (PDF)

Association of programmed death ligand‐1 (PD‐L1) expression with treatment outcomes in patients with BRAF mutation‐positive melanoma treated with vemurafenib or cobimetinib combined with vemurafenib

Pigment cell and melanoma research, 2018-07, Vol.31 (4), p.516-522

2018

Volltextzugriff (PDF)

B-cell Lymphomas With Concurrent IGH-BCL2 and MYC Rearrangements Are Aggressive Neoplasms With Clinical and Pathologic Features Distinct From Burkitt Lymphoma and Diffuse Large B-cell Lymphoma

The American journal of surgical pathology, 2010-03, Vol.34 (3), p.327-340

2010

Volltextzugriff (PDF)

Beta Blockade and Clinical Outcomes in Aneurysmal Subarachnoid Hemorrhage

The open neurology journal, 2016-12, Vol.10 (1), p.155-163

2016

Volltextzugriff (PDF)

Binding of Taxol to Plastic and Glass Containers and Protein under in Vitro Conditions

Journal of pharmaceutical sciences, 1996-01, Vol.85 (1), p.29-31

1996

Volltextzugriff (PDF)

BMI-1 promotes ewing sarcoma tumorigenicity independent of CDKN2A repression

Cancer research (Chicago, Ill.), 2008-08, Vol.68 (16), p.6507-6515

2008

Volltextzugriff (PDF)

BMI-1 suppresses contact inhibition and stabilizes YAP in Ewing sarcoma

Oncogene, 2011-04, Vol.30 (17), p.2077-2085

2011

Volltextzugriff (PDF)

Clinical features of serous retinopathy observed with cobimetinib in patients with BRAF-mutated melanoma treated in the randomized coBRIM study

Journal of translational medicine, 2017-06, Vol.15 (1), p.146-9, Article 146

2017

Volltextzugriff (PDF)

Cobimetinib (C) + paclitaxel (P) as first-line treatment in patients (pts) with advanced triple-negative breast cancer (TNBC): Updated results and biomarker data from the phase 2 COLET study

Journal of clinical oncology, 2016-05, Vol.34 (15_suppl), p.1074-1074

2016

Volltextzugriff (PDF)

Cobimetinib combined with vemurafenib in advanced BRAF(V600)-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial

The lancet oncology, 2016-09, Vol.17 (9), p.1248-1260

2016

Volltextzugriff (PDF)

1 – 25 von 105

Suche als RSS-Feed

Aktive Filter

PublikationsformTagungsberichte

PublikationsformArtikel

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(102)
Mit Volltextzugriff
(100)

Sprache

Englisch
(105)
Japanisch
(5)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

5-Year Outcomes with Cobimetinib plus Vemurafenib in BRAF V600 Mutation–Positive Advanced Melanoma: Extended Follow-up of the coBRIM Study

5-Year Outcomes with Cobimetinib plus Vemurafenib in BRAFV600 Mutation-Positive Advanced Melanoma: Extended Follow-up of the coBRIM Study

Abstract 4239: Ectopic expression of EWS-FLI1 in human neural crest stem cells induces polycomb genes and maintenance of stemness

Abstract 5169: The polycomb group protein BMI-1 cooperates with Yes-Associated Protein, YAP, to suppress cell contact inhibition in Ewing sarcoma cells

Abstract LB-233: Modeling Ewing sarcoma initiation in human neural crest stem cells

Abstract LB-A09: EED targeted PROTACs degrade EED, EZH2, and SUZ12 in the PRC2 complex

Abstract PR03: Prmt1 and Prmt1-dependent translation initiation are critical vulnerabilities of osteosarcoma

Abstract SY15-01: Modeling the initiation of Ewing sarcoma in human neural crest stem cells

Acceptability and appropriateness of a novel parent-staff co-leadership model for childhood obesity prevention in Head Start: a qualitative interview study

Adverse event (AE) incidence rates with cobimetinib (C) plus vemurafenib (V) treatment: Extended follow-up (f/u) of the phase III coBRIM study

Amination-mediated nano eye-drops with enhanced corneal permeability and effective burst release for acute glaucoma treatment

Application of ion chromatography to the semiconductor industry: I. Measurement of acidic airborne contaminants in cleanrooms

The association of BMI and outcomes in metastatic melanoma: A retrospective, multicohort analysis of patients treated with targeted therapy, immunotherapy, or chemotherapy

Association of Participation in the Oncology Care Model With Medicare Payments, Utilization, Care Delivery, and Quality Outcomes

Association of programmed death ligand‐1 (PD‐L1) expression with treatment outcomes in patients with BRAF mutation‐positive melanoma treated with vemurafenib or cobimetinib combined with vemurafenib

B-cell Lymphomas With Concurrent IGH-BCL2 and MYC Rearrangements Are Aggressive Neoplasms With Clinical and Pathologic Features Distinct From Burkitt Lymphoma and Diffuse Large B-cell Lymphoma

Beta Blockade and Clinical Outcomes in Aneurysmal Subarachnoid Hemorrhage

Binding of Taxol to Plastic and Glass Containers and Protein under in Vitro Conditions

BMI-1 promotes ewing sarcoma tumorigenicity independent of CDKN2A repression

BMI-1 suppresses contact inhibition and stabilizes YAP in Ewing sarcoma

Clinical features of serous retinopathy observed with cobimetinib in patients with BRAF-mutated melanoma treated in the randomized coBRIM study

Cobimetinib (C) + paclitaxel (P) as first-line treatment in patients (pts) with advanced triple-negative breast cancer (TNBC): Updated results and biomarker data from the phase 2 COLET study

Cobimetinib combined with vemurafenib in advanced BRAF(V600)-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial

Cobimetinib combined with vemurafenib in advanced BRAF V600 -mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial

Cobimetinib combined with vemurafenib in advanced BRAFV600 -mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial

Aktive Filter

Suchergebnisse filtern